Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 7/20 | 0.40 |
| ▸ | ACACA | Q13085 | 6/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222880 | 0.93 | CYP8B1 (0.48) | CYP8B1CKS1BSKP1SKP2ACACB | |
| SCHEMBL4069637 | 0.85 | SIRT2 (0.47) | CYP8B1CKS1BSKP1SKP2ACACB | |
| SCHEMBL10078588 | 0.84 | CYP8B1 (0.44) | CYP8B1CKS1BSKP1SKP2KCNH2 | |
| SCHEMBL13527141 | 0.81 | CYP8B1 (0.48) | CYP8B1CKS1BSKP1SKP2KCNH2 | |
| SCHEMBL17861337 | 0.80 | CKS1B (0.48) | CYP8B1CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL1224777 | 0.80 | MAP4K4 (0.51) | CYP8B1CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL1224773 | 0.80 | MAP4K4 (0.51) | CYP8B1CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL13527211 | 0.79 | CYP8B1 (0.45) | CYP8B1CKS1BSKP1SKP2KCNH2 | |
| SCHEMBL3162840 | 0.79 | CYP8B1 (0.47) | CYP8B1CKS1BSKP1SKP2KCNH2 | |
| SCHEMBL1224323 | 0.79 | MAP4K4 (0.58) | CYP8B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915813-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | CYP8B1 902/4885NAMPT 3740/4885CKS1B 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.